Vetoquinol SA (EPA:VETO)

France flag France · Delayed Price · Currency is EUR
72.80
+0.40 (0.55%)
Sep 4, 2025, 1:26 PM CET
0.55%
Market Cap854.01M
Revenue (ttm)539.20M
Net Income (ttm)58.69M
Shares Out11.80M
EPS (ttm)4.98
PE Ratio14.55
Forward PE14.20
Dividend0.89 (1.23%)
Ex-Dividend DateJun 4, 2025
Volume348
Average Volume2,370
Open72.20
Previous Close72.40
Day's Range72.20 - 73.20
52-Week Range63.60 - 98.40
Beta0.75
RSI41.79
Earnings DateSep 11, 2025

About Vetoquinol

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, pigs, dogs, and cats. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of S... [Read more]

Sector Healthcare
Founded 1933
Employees 2,501
Stock Exchange Euronext Paris
Ticker Symbol VETO
Full Company Profile

Financial Performance

In 2024, Vetoquinol's revenue was 539.20 million, an increase of 1.88% compared to the previous year's 529.27 million. Earnings were 58.69 million, an increase of 5.62%.

Financial Statements

News

There is no news available yet.